You are now leaving XTANDI.com
The website you are about to visit is not owned or controlled by Astellas. Astellas are not responsible for the information or services on this site.
NORTHBROOK, Ill., March 31, 2017 /PRNewswire/ -- Astellas today announced that John DeMay has been appointed president, Astellas US Technologies, Inc. (AUST). In this role, DeMay will be responsible for promoting collaboration and cooperation across Pharmaceutical Technology divisions functions in the Americas. He will also serve as the site manager for AUST based in Northbrook and will represent AUST in various Americas management activities. DeMay will also continue in his role as head of Project and Product Management Group reporting to Dr. Katsutoshi Nakamura, head of Project and Product Management within Pharmaceutical Technology.
"John's background and broad experience in this area will help him meet the challenges of this new role, while continuing to grow the strong partnerships that exist within AUST and between AUST and its collaborators," said Nakamura. "He is dedicated to assuring stable global supply of clinical and commercial products for patients."
Previously, DeMay served as executive director, Pharmaceutical Technology Management for AUST. He joined Astellas in 2002 as an associate director of Technical Services and later served as director and senior director of the CMC Technology group within US Pharmaceutical Technology Management.
Throughout his 15-year career at Astellas, DeMay has played an important role in the chemistry, manufacturing and control (CMC) development and CMC project management. He has contributed to the development, introduction and stable supply of several new drug products and marketed products.
DeMay holds a Bachelor of Science in Biology degree with a Chemistry Minor from Michigan Technological University and a Bachelor of Science in Pharmacy degree from Ferris State University.
About Astellas
Astellas is a pharmaceutical company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. For more information on Astellas, please visit our website at www.astellas.us. You can also follow us on Twitter at @AstellasUS, Facebook at www.facebook.com/AstellasUS or LinkedIn at www.linkedin.com/company/astellas-pharma.
SOURCE Astellas
Get only the email alerts you want.
For media inquiries and reporter requests, please email us at corporate.communications@us.astellas.com.
Our communications team will respond to verified media requests within 24-48 hours as appropriate.
If you are not a reporter and need assistance, please visit our contact us page that includes information for patients, healthcare providers and researchers.
This website is intended for U.S. residents only. This website contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, or in different dosages. Nothing contained herein should be considered a solicitation, promotion or advertisement for any drug including those under development. Any information on the products contained herein is not intended to provide medical advice nor should be used as a substitute for the advice provided by your physician or other healthcare provider.
The site uses cookies to provide you with a more responsive and personalized service and to analyze site traffic. By using this site, you accept our use of cookies as described in our privacy policy. Please read our privacy policy for more information on the cookies we use, the processing of your personal data and how to delete or block the use of cookies.